About This Course

Managing chemotherapy-induced neutropenia in 2021 - get the latest updates to improve treatment adherence, increase patient access, and reduce clinic visits during the COVID-19 pandemic.

An interactive course aimed at healthcare professionals (oncologists, general practitioners, nurse practitioners) treating cancer patients receiving chemotherapy.

This course should take you approximately 60 minutes to complete.

Developed together with world-leading experts:

Lee Schwartzberg, MD FACP

West Cancer Center, Germantown, TN, USA

Adam Brufsky, MD PhD

University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Kashyap B Patel, MD

Carolina Blood and Cancer Care Associates, Rock Hill, SC, USA

The course comprises three short interactive modules:

  • febrile neutropenia associated with chemotherapy
  • long-acting G-CSFs in prophylaxis and management 
  • the place of biosimilars in clinical practice

This activity has been approved for AMA PRA Category 1 Credit(s)™ by Indiana University School of Medicine. 

Launch date: 19th April 2021

Expiry date: 19th April 2023

Claim your credit now!

Learning Objectives

By the end of this module, you should:

  • Understand the definition of febrile neutropenia in patients receiving chemotherapy

  • Appreciate the impact both for the patient and the health system

  • Be familiar with risk assessment for the development of serious complications

  • Know the treatment options

Course curriculum

    1. CME Credits

    1. Navigation Instructions

    1. Take this quiz before you start

    2. Pre-Course Quiz

    1. Main Course

    1. Now check how much you have learned.

    1. Download the summary sheet

About this course

  • Free
  • 7 lessons
  • 0 hours of video content

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Indiana University School of Medicine and S. Karger Publishers Ltd. Indiana University School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Indiana University School of Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Summary

Indiana University School of Medicine (IUSM) policy ensures that those who have influenced the content of a CE activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that IUSM may identify and resolve any conflicts of interest prior to the activity. All educational programs sponsored by Indiana University School of Medicine must demonstrate balance, independence, objectivity, and scientific rigor.

There are no relevant financial relationships with a commercial interest for anyone who was in control of the content of this activity, except:

Dr. Adam Brufsky, MD, PhD, disclosed being a consultant for Sandoz, Amgen, Pfizer, Lilly, and Novartis.  

Dr. Lee Schwartzberg, MD, FACP, disclosed being a consultant for Amgen, Pfizer, Helsinn, Genentech, Genomich Health, BMS, Myriad, AstraZeneca, Bayer, Spectrum, and Napo, and received research funding from Amgen.

Dr. Kashyap B. Patel, MD, disclosed being consultant for Amgen, Pfizer, Sanofi/Aventis, Partner Therapeutics, Sandoz, and Abbvie, and disclosed serving on the speakers bureau for Janssen and Teva.

All conflicts have been resolved.

*Indiana University School of Medicine (IUSM) defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Commercial Support

This activity is supported by an educational grant from Fresenius Kabi SwissBioSim GmbH.